Mallinckrodt (MNK) Tops Q4 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Mallinckrodt (MNK) Tops Q4 EPS by 35c
February 25, 2020 6:05 AM EST
STAINES-UPON-THAMES, United Kingdom, Feb. 25, 2020 /PRNewswire/ --Â Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today reported results for the three months and fiscal year ended Dec. 27, 2019. Unless otherwise noted, the three months and fiscal year comparisons are to the prior year comparable period ended Dec. 28, 2018.
...
More
February 25, 2020 6:00 AM EST
STAINES-UPON-THAMES, United Kingdom, Feb. 25, 2020 /PRNewswire/ --Â Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") today announced that the Company and its specialty generics-focused subsidiaries Mallinckrodt LLC, SpecGx LLC and certain other affiliates (collectively, "Specialty Generics") have reached an agreement in principle on the terms of a global settlement that would resolve all opioid-related claims against the Company, Specialty Generics, and the Company's other subsidiaries. The agreement in principle has been reached with a court-appointed plaintiffs' executive committee representing the interests of thousands of plaintiffs in the opioid multidistrict... More
